MANDEEP BAJAJ to Fatty Acids, Nonesterified
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Fatty Acids, Nonesterified.
Connection Strength
1.959
-
Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes. 2007 Mar; 56(3):743-52.
Score: 0.273
-
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes. 2005 Nov; 54(11):3148-53.
Score: 0.249
-
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004 Sep; 89(9):4649-55.
Score: 0.230
-
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes. 2002 Oct; 51(10):3043-8.
Score: 0.201
-
Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. Am J Physiol Endocrinol Metab. 2002 Aug; 283(2):E346-52.
Score: 0.199
-
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. 2012 Jul; 223(1):204-8.
Score: 0.098
-
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
Score: 0.092
-
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010 Apr; 95(4):1916-23.
Score: 0.084
-
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2007 Jun; 292(6):E1775-81.
Score: 0.068
-
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep; 89(9):4312-9.
Score: 0.057
-
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004 Jun; 28(6):783-9.
Score: 0.056
-
Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep. 2004 Jun; 4(3):213-8.
Score: 0.056
-
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Sep; 287(3):E537-46.
Score: 0.056
-
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Jan; 89(1):200-6.
Score: 0.055
-
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003 Oct; 52(10):2461-74.
Score: 0.054
-
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003 Jun; 52(6):1364-70.
Score: 0.053
-
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002 Jun; 282(6):E1360-8.
Score: 0.049
-
Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem. 2005 Mar 18; 280(11):10290-7.
Score: 0.015
-
Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005 Feb; 90(2):1100-5.
Score: 0.015